Low-Dose Interleukin 2 Shows Promise for Treatment of Ulcerative Colitis

Researchers at Brigham and Women’s Hospital recently published data from an open-label phase 1b/2a trial suggesting induction therapy with low-dose IL-2 is safe for patients with ulcerative colitis and suppresses the disease.
Read More...